CompletedPhase 2NCT05048875

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Anna Durbin, MD, MD
Center for Immunization Research, Johns Hopkins School of Public Health
Intervention: Cohort 1 - Group 1 JNJ High Dose(drug)
Enrollment: 56 enrolled
Eligibility: 18-55 years · All sexes
Timeline: 2022 – 2024

Study locations (2)

Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States
University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont, United States

Collaborators

Janssen, LP · National Institutes of Health (NIH)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05048875 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials